Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.
Earnings & Valuation
This table compares Bluejay Diagnostics and Sight Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bluejay Diagnostics | N/A | N/A | -$7.72 million | ($472.64) | -0.01 |
| Sight Sciences | $79.87 million | 3.55 | -$51.51 million | ($0.90) | -5.96 |
Profitability
This table compares Bluejay Diagnostics and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bluejay Diagnostics | N/A | -432.21% | -345.69% |
| Sight Sciences | -60.63% | -61.59% | -36.11% |
Risk and Volatility
Bluejay Diagnostics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500.
Insider and Institutional Ownership
18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 0.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 28.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and target prices for Bluejay Diagnostics and Sight Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bluejay Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| Sight Sciences | 1 | 3 | 4 | 1 | 2.56 |
Sight Sciences has a consensus price target of $8.30, indicating a potential upside of 54.85%. Given Sight Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Sight Sciences is more favorable than Bluejay Diagnostics.
Summary
Sight Sciences beats Bluejay Diagnostics on 11 of the 14 factors compared between the two stocks.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
